

Docket No.
3221/US


FEB 07 2005

Invention: Osteoarthritis Tissue Derived Nucleic Acids, Polypeptides, Vectors, and Cells

* 02/08/2005 RFEKADU1 00000010 191025 09765231
01 FC:1253 1020.00 DA

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Large Entity)**


Docket No.
3221/US



The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of _____ for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. **19-1025** in the amount of **\$1,020.00**
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Signature

Phillip B. Polster, II
Pharmacia Corporation of Pfizer Inc.
Patent Department
P.O. Box 1027
St. Louis, MO 63006

Dated: February 4, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
02/04/2005

(Date)



Signature of Person Mailing Correspondence

Angela D. Smith

Typed or Printed Name of Person Mailing Correspondence

CC: